LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, has announced that the Annual Meeting of Shareholders will be held at their corporate headquarters 15350 Sherman Way, Suite 423, Van Nuys, California on Thursday, June 7, 2018 at 8 a.m. Pacific Standard time (PST).
“This will be the last Annual Meeting of Shareholders held at this location given that HemaCare will be relocating to its expansion facility in the fourth quarter of this year,” said Pete van der Wal, Chief Executive Officer for HemaCare. “The new single story 40,000 square foot complex facilitates scalability to support HemaCare’s continued rapid growth,” said van der Wal.
HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution. For 40 years, HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research, cell therapy clinical trials and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.
For more information please visit www.hemacare.com.